Cornelius Wilson, MD
Adolescent Medicine · Houston, TXNPI 1215032586
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $313 and has fallen 74.5% since, to $80 in 2025.
Across 32 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$133
- Boston Scientific$116
- Cranial Technologies, Inc$112
- Supernus Pharmaceuticals, Inc.$50
- Phadia US Inc.$47
- Kowa Pharmaceuticals America, Inc.$37
- plus $181 from 8 others
What the payments were for
- Food & beverage$678100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $133 |
| Boston Scientific | 2 | $116 |
| Cranial Technologies, Inc | 8 | $112 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Phadia US Inc. | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| AstraZeneca | 2 | $34 |
| Jazz Pharmaceuticals Inc. | 1 | $32 |
| Exact Sciences | 1 | $29 |
| Cumberland Pharmaceuticals, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Alk-abello, Inc | 1 | $15 |
| Tris Pharma Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESONATE$101
How this compares
$678 in reported general payments places this provider in the 60th percentile of 68 adolescent medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $73,927 |
| JanuviaSitagliptin Phosphate | 18 | $26,944 |
| EliquisApixaban | 31 | $25,505 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,791 |
| TrulicityDulaglutide | 11 | $11,096 |
| XareltoRivaroxaban | 14 | $9,505 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 307 | $8,472 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,625 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 25 | $4,205 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,815 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,791 |
| Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein | 16 | $2,627 |
| Gabapentin | 197 | $2,355 |
| Ventolin HfaAlbuterol Sulfate | 35 | $2,111 |
| Omeprazole | 97 | $1,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $133 | $25,50531 claims |
| AstraZenecaSymbicort | $34 | $7,62525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 adolescent medicine providers in Texas.
Other adolescent medicine in Houston
- Amy MiddlemanHouston$70K
- Surainder AjmaniHouston$3K
- Sharonda TaylorHouston$2K
- Renu GargHouston$2K
- Michael FunkeHouston$2K
- Shannon HayesHouston$2K
- Syed RizviHouston$549
- Mona EissaHouston$410
- Laura BenjaminsHouston$230
- Surinder KaulHouston$155
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.